Coherus BioSciences, Inc.

CHRS

Explore Our Financial Data > Companies > Coherus BioSciences, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
CHRS
CIK0001512762
SIC2836
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupBiological Products, Except Diagnostic Substances

Contact

AddressC/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
Website coherus.com
Phone(650) 649-3530
CEODenny M. Lanfear
Employees330

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$272.25 million
Pre-Tax Income$49.14 million
Net Income$-130.94 million
Net Income to Common$-130.94 million
EPS$-1.15
View All
Balance Sheet
Cash$82.41 million
Assets$371.07 million
Liabilities$554.54 million
Common Equity$-183.47 million
Liabilities & Equity$371.07 million
View All
Cash Flow Statement
Net Income$-130.94 million
Cash From Operating Activities$500,000.00
Cash From Investing Activities$10.07 million
Cash From Financing Activities$-188.12 million
Change in Cash$-177.55 million
View All
Calculations
NOPAT$-89.32 million
EBITDA$-83.81 million
Price to EarningsN/A
Price to BookN/A
ROE98.70%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.c

Article Link

Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?

Krystal Biotech (KRYS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Article Link

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner’s Substack. In this article, we will summarize the bulls’ thesis on CHRS. Coherus BioSciences, Inc. (CHRS)’s share was trading at $0.77 as of 30th May. CHRS’s trailing P/E was 1.77 according to Yahoo Finance. Coherus BioSciences (CHRS), long overlooked by Wall Street, is […]

Article Link

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today to better align with its exclusive focus on proprietary innovative immuno-oncology medicines. “The field of cancer immunotherapy has been reinvigorated by the promise and power of combination therapies. Coherus Oncology has the expertise and pipeline to become a sign

Article Link

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)

– First patient dosed in a Phase 1b/2 study evaluating STC-15, a METTL3 inhibitor, in combination with LOQTORZI, a next-generation PD-1 inhibitor –REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), today announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor, in a Phase 1b/2 study for the treatment o

Article Link